HanchorBio Expands Global Patent Protection for HCB101 with Taiwan Grant
Taiwan grant adds to issued patents in the United States and Japan, further strengthening HCB101’s cross-border IP estate and supporting long-term development and partnering strategy
HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, today announced that the Taiwan Intellectual Property Office has granted a patent covering HCB101, the company’s lead engineered SIRPα fusion protein, under the title “ENGINEERED SIRPα VARIANTS AND METHODS OF USE THEREOF.” The Taiwan patent certificate number is I916300.
The grant further enhances HanchorBio’s intellectual property position regarding the core molecular design and therapeutic application of HCB101 as the program progresses through clinical development and global partnership discussions.
HCB101 is a rationally engineered SIRPα fusion protein developed using HanchorBio’s proprietary FBDB™ platform. It is designed to target the CD47–SIRPα innate immune checkpoint with a differentiated profile intended to enhance blockade of CD47 on tumor cells while reducing binding to normal blood cells. This design is intended to support improved tolerability, broader combination potential, and greater clinical utility in immuno-oncology.
“The Taiwan patent grant further strengthens the global intellectual property foundation for HCB101 and reflects our ongoing commitment to developing a differentiated and strategically valuable program,” said Scott Liu, Ph.D., Chairman and Chief Executive Officer of HanchorBio. “With patents now issued in the United States, Japan, and Taiwan, we are broadening protection for the core innovation behind HCB101 in key jurisdictions for scientific leadership, clinical development, and future collaborations.”
The Taiwan patent is strategically significant not only because it provides protection in another Asian jurisdiction but also because it strengthens protection in HanchorBio’s local innovation hub, where the original invention and platform technologies were developed. For global investors and potential partners, securing protection in the home jurisdiction enhances the company’s control over the core intellectual property behind the program and deepens the patent portfolio supporting HCB101.
The Taiwan grant expands HanchorBio’s expanding global IP portfolio for HCB101. The program previously received U.S. Patent No. 12,447,195 in October 2025 and Japan Patent No. 7795041 in January 2026. Now that patents have been issued in the United States, Japan, and Taiwan, HanchorBio has established a strong early patent foundation across key jurisdictions related to the invention’s origin, pharmaceutical partnerships, and future commercial strategy.
As HCB101 advances through clinical development, HanchorBio believes this growing patent portfolio will play a key role in protecting the program’s unique molecular design, enhancing its competitive position, and supporting future licensing and strategic collaborations. The U.S., Japan, and Taiwan grants collectively provide issued patent protection across a significant cross-border IP footprint, boosting the asset’s long-term strategic value as development continues.
HanchorBio is advancing a pipeline of innovative biologics for oncology and autoimmune diseases through its proprietary platform technologies. The company remains focused on combining scientific innovation, clinical development, and global intellectual property strategies to advance new therapies for patients with significant unmet medical needs.
About HCB101
HCB101 is an engineered SIRPα–IgG4 Fc fusion protein designed to target the CD47–SIRPα innate immune checkpoint with a differentiated profile intended to enhance tumor-cell blockade while reducing binding to normal blood cells. Developed using HanchorBio’s proprietary FBDB™ platform, HCB101 is being advanced as a potential backbone for innate immune checkpoint therapy in oncology.
About HanchorBio
HanchorBio (TPEx: 7827) is a global clinical-stage biotechnology company developing next-generation immunotherapies for oncology and autoimmune diseases. With operations in Taipei, Shanghai, and the San Francisco Bay Area, the company is advancing a pipeline of differentiated biologics built on its proprietary Fc-based designer biologics (FBDB™) platform. HanchorBio’s programs are designed to address unmet medical needs through advanced molecular engineering, clinical development, and scalable manufacturing strategies.
漢康生技融合蛋白創新藥HCB101獲台灣專利核准 持續推進全球智財布局
繼美國與日本專利核准，又獲台灣專利核發，強化HCB101跨區域智慧財產保護，支持長期開發與國際合作策略
漢康生技旗下創新融合蛋白生物藥HCB101正式獲得台灣經濟部智慧財產局專利核准，專利名稱為「ENGINEERED SIRPα VARIANTS AND METHODS OF USE THEREOF（經工程改造之 SIRPα 變體及其使用方法）」，專利證字號為I916300。HCB101為工程化 SIRPα 融合蛋白創新生物藥，此次專利的取得，進一步強化HCB101核心分子設計及治療應用上的智慧財產布局，隨著HCB101持續推進臨床開發及全球合作洽談，此次專利核准也為後續臨床推進、國際授權與策略合作奠定更穩固的基礎。
HCB101為漢康生技運用自有FBDB™平台所開發之工程化SIRPα融合蛋白生物藥，針對CD47–SIRPα先天免疫檢查點，藉由優化分子設計提升對腫瘤細胞表面 CD47 的功能性阻斷，同時降低與正常血球的結合，展現差異化的產品設計與臨床發展潛力。此一設計可望支持更佳的耐受性、更廣泛的合併用藥潛力，以及在免疫腫瘤治療領域更高的臨床應用價值。
漢康生技董事長暨執行長劉世高博士表示：「此次台灣專利核准，進一步強化了HCB101的全球智慧財產基礎，也體現我們持續打造具差異化與策略價值產品的承諾。隨著HCB101已在美國、日本與台灣取得專利，我們正持續在關鍵區域擴大全球保護範圍，以支持科學創新、臨床開發及未來合作布局。」
此次台灣專利獲准，不僅在於將HCB101的保護範圍拓展至另一個亞洲重要市場，也進一步強化漢康生技作為原始創新與平台技術發源地的在地智財保護。對全球投資人與潛在合作夥伴而言，於發明來源地取得專利保護，有助於進一步強化公司對核心智慧財產的掌握，並深化HCB101整體專利組合的完整性；也代表漢康生技進一步擴大HCB101的全球智財版圖。繼2025年10月取得美國專利（US Patent No. 12,447,195）後，HCB101又於2026年1月取得日本專利（Japan Patent No. 7795041），持續在重要醫藥市場建立完整的智財保護網絡。
隨著美國、日本與台灣三地專利相繼核發，漢康生技已在與該發明起源、藥業合作及未來商業化策略密切相關的關鍵區域，建立起堅實的專利基礎。
隨著 HCB101 持續推進臨床開發與國際合作，逐步擴大而穩健的專利布局將有助於保護核心創新成果──獨特的分子設計，提升產品在全球市場的授權合作價值與競爭優勢。台灣專利的取得，不僅彰顯漢康生技在免疫腫瘤治療領域的研發實力，也進一步鞏固公司以創新融合蛋白技術拓展全球市場的戰略基礎。而美國、日本與台灣的專利核准，已共同構成HCB101重要的跨國智財保護版圖，並隨著後續開發推進，持續提升此項資產的長期策略價值。
漢康生技將持續運用自有平台優勢，推進腫瘤與自體免疫疾病領域的創新生物藥開發，並透過全球智財布局、臨床推進與策略合作，深化產品國際競爭力，致力將具差異化優勢的創新療法帶給全球的病患。
關於 HCB101
HCB101 為漢康生技以 FBDB™ 平台理性設計開發之 SIRPα–IgG4 Fc 融合蛋白，旨在選擇性阻斷 CD47–SIRPα 先天免疫檢查點，同時降低血液學毒性。不同於早期的抗 CD47，HCB101 在保留巨噬細胞介導抗腫瘤活性的同時，降低對紅血球 CD47 的結合能力，以克服過去限制該療法發展的關鍵挑戰。
透過 AI 輔助結構建模，HCB101 對腫瘤細胞上的 CD47 具差異化結合特性，並維持對紅血球 CD47 的低親和力。其安全性、受體佔有率與藥理特性，皆有利於與既有腫瘤治療方案整合。目前 HCB101 正於胃癌、大腸直腸癌及頭頸癌等適應症持續進行劑量遞增與臨床二期擴展研究。
綜合上述特質，HCB101 已定位為具備差異化的先天免疫檢查點骨幹（Backbone），並具備橫跨實體腫瘤與血液腫瘤的廣泛潛力。
關於漢康生技
漢康生技（證券代碼：7827.TPEx）總部位於台北、上海與舊金山灣區，是一家全球臨床階段生技公司，專注於腫瘤免疫治療與免疫相關疾病新藥開發。公司由具備生物藥研發與全球開發實績的團隊領導，致力於透過創新分子設計重塑癌症治療格局。
漢康生技所開發的 Fc-based designer biologics（FBDB™）平台可設計多功能生物藥，透過多元標的組合，同步激活先天與後天免疫路徑，並克服現有 anti-PD1/L1 免疫療法所面臨的挑戰。透過在多功能生物藥研發領域的突破，以及具備高擴展性的 CMC（化學製造與管制）策略，漢康生技正加速推進創新藥物管線，以解決尚未被滿足的重大醫療需求。